Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deferred Tax Liability: 2019-2020

Historic Non-Current Deferred Tax Liability for Silence Therapeutics (SLN) over the last 2 years, with Dec 2020 value amounting to $32,104.

  • Silence Therapeutics' Non-Current Deferred Tax Liability rose 6.98% to $33,011 in Q4 2020 from the same period last year, while for Dec 2020 it was $33,011, marking a year-over-year increase of 6.98%. This contributed to the annual value of $32,104 for FY2020, which is 4.76% up from last year.
  • Latest data reveals that Silence Therapeutics reported Non-Current Deferred Tax Liability of $32,104 as of FY2020, which was up 4.76% from $30,644 recorded in FY2019.
  • Silence Therapeutics' 5-year Non-Current Deferred Tax Liability high stood at $32,104 for FY2020, and its period low was $30,644 during FY2019.
  • Its 2-year average for Non-Current Deferred Tax Liability is $31,374, with a median of $31,374 in 2019.
  • Data for Silence Therapeutics' Non-Current Deferred Tax Liability shows a peak YoY grew of 4.76% (in 2020) over the last 5 years.
  • Silence Therapeutics' Non-Current Deferred Tax Liability (Yearly) stood at $30,644 in 2019, then increased by 4.76% to $32,104 in 2020.